

READING BOROUGH COUNCIL

REPORT BY DIRECTOR OF PUBLIC HEALTH

TO:	HEALTH & WELLBEING BOARD		
DATE:	13 DECEMBER 2013	AGENDA ITEM:	14
TITLE:	Pharmaceutical Needs Assessment - Scoping document		
LEAD COUNCILLOR:	CLLR HOSKIN	PORTFOLIO:	HEALTH
SERVICE:	PUBLIC HEALTH	WARDS:	BOROUGHWIDE
LEAD OFFICER:	DR LISE LLEWELLYN	TEL:	01344 355206
JOB TITLE:	STRATEGIC DIRECTOR OF PUBLIC HEALTH	E-MAIL:	lise.llewellyn@bracknell-forest.gov.uk

1. PURPOSE OF REPORT AND EXECUTIVE SUMMARY

1.1. Purpose of this report

This report sets out the scope of the Pharmaceutical Needs Assessment (PNA). It states what will be included in the PNA, the methodology to be used and the timeline for delivery of the project.

2. RECOMMENDED ACTION

2.1 *For information only.*

3. POLICY CONTEXT

3.1. The Health and Social Care Act 2012 transferred responsibility for developing and updating the Pharmaceutical Needs Assessments (PNAs) to health and wellbeing boards (HWBs). Responsibility for using PNAs as the basis for determining market entry to a pharmaceutical list was transferred from PCTs (Primary Care Trusts) to NHS England from 1 April 2013. The first HWBs' PNA needs to be published by 1st April 2015. It needs to be kept up-to-date through supplementary updates and fully revised every three years.

3.2. Each Health and Well-being Board must in accordance with Department of Health regulations—

- (a) assess needs for pharmaceutical services in its area, and
- (b) publish a statement of its first assessment and of any revised assessment

3.3. The PNA will provide information on the current pharmaceutical services in Berkshire and identify gaps in the current service provisions, taking into account any known future needs.

4. THE PROPOSAL

4.1. Purpose of the PNA

The PNA will be used by NHS to commission pharmaceutical services in Berkshire. It will also be used by the public health team in Reading Unitary Authority to commission locally enhanced services.

4.2. Importance of PNA to Reading Health and Wellbeing Board

Reading HWB will need to publish its PNA by 1st April 2015. This will require board-level sign-off and a period of public consultation beforehand. Failure to produce a robust PNA could lead to legal challenges because of the PNA's relevance to decisions about commissioning services and new pharmacy openings.

HWB will also need to ensure that the NHS Commissioning Board and its Area Teams have access to the PNA.

4.3. What will be included in the PNA [1, 2]

What will be included	Method
<p>1. Necessary services – current provision Pharmaceutical services which are identified as services that are provided: (a) in Berkshire and which are necessary to meet its need for pharmaceutical services (b) outside Berkshire but which nevertheless contribute towards meeting its need for pharmaceutical services</p>	<p>Current services will be mapped to assess the adequacy of current pharmaceutical service provision</p>
<p>2. Necessary services – gaps in provision Pharmaceutical services that have been identified as services that are not provided in Berkshire but which will - (a) need to be provided (whether or not they are located in the area of the HWB) in order to meet a current need for pharmaceutical services, or pharmaceutical services of a specified type, in its area; (b) will, in specified future circumstances, need to be provided (whether or not they are located in the area of the HWB) in order to meet a future need for pharmaceutical services, or pharmaceutical services of a specified type, in its area.</p>	<p>Gaps will include gaps in pharmaceutical health needs and gaps by service type. These may be gaps in provision of essential services, opening hours, provision of dispensing services or access to pharmaceutical services</p>
<p>3. Other relevant services – current provision Pharmaceutical services that are identified as services that are provided- (a) in Berkshire or in neighbouring counties, and which, although they are not necessary to meet the need for pharmaceutical services in Berkshire, nevertheless resulted in improvements, or better access to pharmaceutical services (b) in or outside Berkshire and, which do not fall under “necessary” category, help the</p>	<p>These may be pharmaceutical services that provide improvements to the provision or better access for the public whether at the current time or in the future.</p>

pharmaceutical service provision in Berkshire	
<p>4. Improvements and better access - gaps in provision</p> <p>Pharmaceutical services which are identified as services that are not provided in Berkshire but which -</p> <p>(a) will, if they were provided, secure improvements, or better access to pharmaceutical services, or pharmaceutical services of a specific type</p> <p>(b) will, if in specified future circumstances they were provided, secure future improvements, or better access, to pharmaceutical services, or pharmaceutical services of a specified type</p>	<p>These may be services that are not currently being provided but which will be needed to secure future improvements to pharmaceutical services – common examples are major industrial, communications or housing developments, service redesign as set out in, for example, the Joint Health and Wellbeing Strategy, or re-provision.</p>
<p>5. Other services</p> <p>Any NHS services provided or arranged by HWBs, NHS Commissioning Board, a Clinical Commissioning Board (CCG), an NHS trust or an NHS foundation trust, which affect-</p> <p>(a) the need for pharmaceutical services, or pharmaceutical services of a specified type, in Berkshire</p> <p>(b) whether further provision of pharmaceutical services in Berkshire would secure improvements, or better access to pharmaceutical services, or pharmaceutical services of a specific type in its area.</p>	<p>There may be services provided or arranged by the HWBs, NHS England, a CCG, an NHS trust (including foundation trusts) which could, if they were included in a PNA, be provided by pharmaceutical services contractors.</p>

4.4. Methodology

There will be one PNA document for Berkshire, within which each of the six individual local authorities will have their own section.

The process will be as follows:

- 1) Existing pharmaceutical services in Berkshire will be mapped against population density and against rate of long term diseases
- 2) Joint Strategic Needs Assessment (JSNA) and other relevant existing documents will be used to identify health needs of the population
- 4) Users' views will be obtained through a questionnaire for the public using pharmacy services and another questionnaire for the pharmacists
- 5) Key stakeholders will be asked for their input through face-to-face meetings

6) Draft report will be sent to the six Health and Wellbeing Boards for their approval before sending it out for stakeholder consultations

7) Stakeholder consultation will be held

8) Final report will be sent to the six Health and Wellbeing Boards in Berkshire for approval before publishing it

Following stakeholders will be consulted:

- Local Pharmaceutical Committee for Berkshire
- Berkshire Local Medical Committee
- Berkshire CCGs
- Any persons on the pharmaceutical lists and any dispensing doctors list for Berkshire population
- Any LPS chemist with whom the NHS England has made arrangements for the provision of any local pharmaceutical services for Berkshire population
- Local Health Watch organisations, and any other patient, consumer or community group in Berkshire, which has an interest in the provision of pharmaceutical services in Berkshire
- NHS Trusts
- Thames Valley NHS England Area Team
- Neighbouring Health and Wellbeing Boards

4.5. Timelines:

Milestones	Deadline	Completed?
Scoping	November 2013	Yes
Meeting commissioners (NHS Thames valley Area Team and CCGs), public health consultants, LPC and Pharmacy Network lead for Berkshire	November – December 2013	In progress
User and pharmacist surveys	January 2014	Planning in progress
Writing first draft	January 2014	
Incorporation of survey results into draft report	February 2014	

Consultation period	March - April 2014	
Analysis of consultation results	May 2014	
Final report	31 st May 2014	

References:

1. Department of Health: Pharmaceutical Needs Assessment Information Pack May 2013

<https://www.gov.uk/government/publications/pharmaceutical-needs-assessments-information-pack> (last accessed on 5th November 2013)

2. UK Legislations: National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013

<http://www.legislation.gov.uk/uksi/2013/349/regulation/8/made> (last accessed on 5th November 2013)